Browsing by Author "Castro-Iglesias, Ángeles"
Now showing items 1-20 of 57
-
Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain
Castro-Iglesias, Ángeles; Díaz, Pilar; Domingo, Pere; García-Yubero, Cristina; Losa-García, Juan E.; Castro-Salomó, Antoni G.; Vidal-Vilar, Neus; Aceituno, Susana (Elsevier, 2022)[Abstract] Objective. To assess the use of resources and the costs associated with following up patients infected with the human immunodeficiency virus after discontinuation of an antiretroviral treatment and initiation ... -
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas, Berta; Grandal, Marta; Pértega-Díaz, Sonia; Cañizares, Angelina; Castro-Iglesias, Ángeles; Mena, Álvaro; Rodríguez-Osorio, Iria; Tabernilla, Andrés; Pedreira, José D.; Poveda, Eva (Oxford University Press, 2015-12-24)[Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ... -
Cancer incidence in persons living with HIV
Meijide, Héctor; Mena, Álvaro; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Poveda, Eva (Oxford University Press para Infectious Diseases Society of America, 2016-11-14) -
Caracterización epidemiológica, clínica y virológica de los nuevos diagnósticos de infección por VHC en Galicia (2014-2015)
Pernas, Berta; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Trigás, M.; Morano, L.; Mariño, A.; Rodríguez-Osorio, Iria; Ocampo, A.; Pereiro, C.; Poveda, Eva (Elsevier, 2016) -
Characterization of chronic HCV infection in Northwest Spain: impact of the treatment strategic plan of the Spanish National Health Service on HCV cure
Grandal, Marta; Pernas, Berta; Mariño, Ana; Álvarez, Hortensia; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Mena, Álvaro; Delgado, Manuel; Pértega-Díaz, Sonia; Poveda, Eva (Wiley, 2017-03-14)[Abstract] The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected ... -
Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis
Mena, Álvaro; Vázquez-Rodríguez, Pilar; Castro-Iglesias, Ángeles; López, Soledad; Bello, Laura; Pedreira, José D. (Oxford, 2011-01-22) -
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
Cid-Silva, Purificación; Llibre, Josep M.; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Wiley, 2017-07-16)[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of ... -
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial
Labarga, Pablo; Barreiro, Pablo; Silva, Alfredo da; Guardiola, Josep María; Rubio, Rafael; Aguirrebengoa, Koldo; Miralles, Pilar; Portu, Joseba; Téllez, María Jesús; Morano, Luis; Castro-Iglesias, Ángeles; Pineda, Juan Antonio; Terrón, Alberto; Hernández-Quero, José; Mariño, Ana; Ríos, María José; Echeverría, Santiago; Asensi, Víctor; Vispo, Eugenia; Soriano, Vincent (Oxford, 2012-07-17)[Abstract] BACKGROUND: Ribavirin (RBV) exposure seems to be critical to maximize treatment response in human immunodeficiency virus (HIV)-positive patients with chronic hepatitis C virus (HCV) infection. METHODS: ... -
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
Mena, Álvaro; Cid-Silva, Purificación; Dueñas, Carlos; Garcinuño, María Ángeles; Lorenzo, Juan Francisco; Margusino-Framiñán, Luis; Quiñones, Marina; Grande, Carmen; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles (Taylor & Francis, 2019-01-03)[Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in ... -
DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: a retrospective study
Jiménez-Sousa, María Ángeles; Jiménez, José Luis; Fernández-Rodríguez, Amanda; Bellón, José María; Rodríguez, Carmen; Riera, Melchor; Portilla, Joaquín; Castro-Iglesias, Ángeles; Muñoz-Fernández, María Ángeles; Resino, Salvador (Springer, 2019-10-23)[Abstract] Background. Most of the circulating Vitamin D (VitD) is transported bound to vitamin D-binding protein (DBP), and several DBP single nucleotide polymorphisms (SNPs) have been related to circulating VitD concentration ... -
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Chen, Qian; Perales, Celia; Soria, María Eugenia; García-Cehic, Damir; Gregori, Josep; Rodríguez-Frías, Francisco; Buti, M.; Crespo, Javier; Calleja, J.L.; Tabernero, David; Vila Salvador, Marta; Lázaro, Fernando; Rando-Segura, Ariadna; Nieto-Aponte, Leonardo; Llorens-Revull, Meritxell; Cortese, Maria Francesca; Fernández, Irati; Castellote, José; Niubó, Jordi; Imaz, Arkaitz; Delgado, Manuel; Cañizares, Angelina; Castro-Iglesias, Ángeles (Elsevier, 2019-12-16)[Abstract] A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was ... -
Despistaje de la infección por el virus de inmunodeficiencia humana en Atención Primaria mediante indicadores de sospecha: estudio DIVAPIS
Ocampo Hermida, Antonio; Longueira Suárez, Rebeca; Castro-Iglesias, Ángeles; Asorey Carballeira, Ángel; De la Fuente Aguado, Javier (Sociedade Galega de Medicina Interna (SOGAMI), 2019-10)[Resumen] Introducción: El diagnóstico precoz de la infección por VIH es fundamental para mejorar el pronóstico de la enfermedad y evitar nuevos contagios. Atención Primaria (AP), al ser el primer nivel asistencial al que ... -
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study
Fernández-Bargiela, Noelia; Rotea-Salvo, Sandra; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Mena-De-Cea, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2020-10-13)[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse ... -
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
Delgado, Elena; Benito, Sonia; Montero, Vanessa; Cuevas, María Teresa; Fernández-García, Aurora; Sánchez-Martínez, Mónica; García-Bodas, Elena; Díez-Fuertes, Francisco; Gil, Horacio; Cañada, Javier; Carrera, Cristina; Martínez-López, Jesús; Sintes, Marcos; Pérez-Álvarez, Lucía; Thomson, Michael M.; Castro-Iglesias, Ángeles (Frontiers, 2019-08-03)[Abstract] In Western Europe, the HIV-1 epidemic among men who have sex with men (MSM) is dominated by subtype B. However, recently, other genetic forms have been reported to circulate in this population, as evidenced ... -
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena, Álvaro; Rodríguez-Osorio, Iria; Pernas, Berta; Delgado, Manuel; Pértega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (Sociedad Española de Quimioterapia, 2019)[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ... -
Effectiveness and safety of direct‐acting antivirals in hepatitis C infected patients with mental disorders: results in real clinical practice
Bobadilla-Pérez, Eva; Cid-Silva, Purificación; Rodríguez‐Sotelo, Alejandro; Yáñez‐Rubal, Juan C.; Mena, Álvaro; Suárez-López, Francisco; Prieto‐Pérez, Andrea; Giménez‐Arufe, Víctor; Delgado, Manuel; Sanclaudio‐Luhia, Ana I.; Martín‐Herranz, Isabel; Castro-Iglesias, Ángeles; Margusino-Framiñán, Luis (Willey Online Library, 2020-03-17)[Abstract] The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ... -
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Rotea-Salvo, Sandra; Mena, Álvaro; Suárez-López, Francisco; Vázquez-Rodríguez, Pilar; Delgado, Manuel; Sanclaudio-Luhia, Ana I.; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (BMJ Publishing Group, 2020-02-07)[Abstract] Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ... -
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort
Alonso, S.; Riveiro-Barciela, M.; Fernández, I.; Rincón, D.; Real, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernández-Carrillo, C.; Polo, B.; Carrión, J.A.; Gómez, A.; Devesa, M.J.; Baliellas, C.; Castro-Iglesias, Ángeles; Ampuero, J.; Granados, R.; Pascasio, J.M.; Rubín, A.; Salmerón, J.; Badia, E.; Planas, J.M.M.; Lens, S.; Turnes, J.; Montero, J.L.; Buti, M.; Esteban, R.; Fernández-Rodríguez, C.M. (Wiley, 2016-11-09)[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or ... -
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study
Londoño, M.C.; García-Buey, L.; Mallolas, J.; Barril, Guillermina; Ahumada, A.; Riveiro-Barciela, M.; Muñoz-Gómez, R.; Roget, M.; Serra, M.A.; Devesa, M.J.; Navascues, C.; Baliellas, C.; Aldamiz-Echevarría, T.; Gutiérrez, M.L.; Carmona, I.; Polo-Lorduy, B.; Bonet, L.; García-Samaniego, J.; Jiménez, M.; Prieto, M.; Moran, S.; Castro-Iglesias, Ángeles; Delgado, M.; Gea, F.; Martín-Granizo, I.; Montes, M.; Morano, L.; Castaño, M.A.; De los Santos, I.; Laguno, M.; Losa, J.E.; Montero, M.; Rivero, A.; Manzanares, A.; De Álvaro, C. (Elsevier, 2017) -
Efficacy and safety of HCV-treatment with direct-acting antiviral agents interferon-free, in patients with severe renal impairment in clinical practice
Cabezas, Joaquín; Londoño, M.C.; Llerena, S.; Muñoz, R.; Baliellas, C.; Buti, M.; Pascasio, J.M.; Sáez-Royuela, F.; García-Samaniego, J.; Vega, J. de la; Sánchez-Pobre, P.; Álvarez-Navascues, C.; Carrión, J.A.; Gea, F.; Morillas, R.M.; Fernández-Bermejo, M.; Castro-Iglesias, Ángeles; Rivero, M.; Fernández, J.R.; Berenguer, M.; Moreno, J.J.; Rincón, D.; Calleja, J.L.; Crespo, J. (Elsevier, 2016)